Risk category | Tumors |
No significant risk | - Benign tumors in which malignancy is excluded
|
Minimal risk (<0.1% transmission) | - Basal cell carcinoma, skin
|
- Squamous cell carcinoma, skin without metastases
|
- Carcinoma in situ, skin (nonmelanoma)
|
- In situ cervical carcinoma
|
- In situ vocal cord carcinoma
|
- Superficial (noninvasive) papillary carcinoma of bladder (T0N0M0 by TNM stage) (non-kidney transplant only)¶
|
- Solitary papillary thyroid carcinoma, ≤0.5 cm
|
- Minimally invasive follicular carcinoma, thyroid, ≤1 cm
|
- (Resected) solitary renal cell carcinoma, ≤1 cm, well differentiated (Fuhrman 1 to 2)Δ
|
Low risk (0.1 to 1% transmission) | - (Resected) solitary renal cell carcinoma, >1 and ≤2.5 cm, well differentiated (Fuhrman 1 to 2)Δ
|
- Low-grade CNS tumor (WHO grade I or II)
|
- Primary CNS mature teratoma
|
- Solitary papillary thyroid carcinoma, 0.5 to 2 cm
|
- Minimally invasive follicular carcinoma, thyroid, 1 to 2 cm
|
- History of treated non-CNS malignancy (≥5 years prior) with >99% probability of cure
|
Intermediate risk (1 to 10% transmission) | - Breast carcinoma (stage 0, ie, carcinoma in situ)
|
- Colon carcinoma (stage 0, ie, carcinoma in situ)
|
- (Resected) solitary renal cell carcinoma T1b (4 to 7 cm) well differentiated (Fuhrman 1 to 2) stage IΔ[1]
|
- History of treated non-CNS malignancy (≥5 years prior) with probability of cure between 90 and 99%
|
High risk (>10% transmission) | |
- Breast carcinoma >stage 0 (active)◊
|
- Colon carcinoma >stage 0 (active)◊
|
|
- CNS tumor (any) with ventriculoperitoneal or ventriculoatrial shunt, surgery (other than uncomplicated biopsy), irradiation, or extra-CNS metastasis
|
- CNS tumor WHO grade III or IV§
|
|
- History of melanoma, leukemia or lymphoma, small cell lung/neuroendocrine carcinoma
|
- Any other history of treated non-CNS malignancy either (a) with insufficient follow-up to predict behavior, (b) considered incurable, or (c) with probability of cure <90%
|
|
|
- Lung cancer (stages I to IV)[1]
|
- Renal cell carcinoma >7 cm or stage II to IV[1]
|
- Small cell/neuroendocrine carcinoma, any site of origin
|
- Active cancer not listed elsewhere¥
|